Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively) and showed the largest increase in total prescribing from September to December 2025
Of the more than 20,000 people surveyed by the firms research arm, nearly 18 percent said they regained all the weight theyd lost but still, 56 percent said that they kept the weight off, and more than half of those respondents said they continued to lose weight in the year after stopping their injections
I was drinking water wildly, which isn't like me
Losing weight too quickly without adequate protein intake and appropriate resistance exercise can lead to loss of lean muscle mass
The development of tirzepatide represents a significant advance beyond selective GLP-1 receptor agonists such as liraglutide, dulaglutide, and semaglutide, which have been the cornerstone of incretin-based therapy over the past decade (Fras et al
US$ 21.90
US$ 26.66
US$ 27.69
US$ 25.53
US$ 23.51
